Pulsenmore

Pulsenmore EBITDA Growth YoY

The Year-over-Year EBITDA Growth of Pulsenmore (PLSM.TA) as of Nov 2, 2026 is 69.21 %. In the previous year, Year-over-Year EBITDA Growth was 25.68 % — a change of 169.53% (higher).

EBITDA Growth YoY

69.21 %

YoY

169.53%

Last updated:

Year-over-Year EBITDA Growth of Pulsenmore is 2025 69.21 % . Year-over-Year EBITDA Growth of Pulsenmore was 2024 25.68 % . It decreases by 169.53% higher compared to the previous year.

The Pulsenmore EBITDA Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Growth YoY
Date
EBITDA Growth YoY
Jan 1, 2020
-227.06 ILS
Jan 1, 2021
-93.54 ILS
Jan 1, 2022
-76.69 ILS
Jan 1, 2023
-20.21 ILS
Jan 1, 2024
25.68 ILS
Jan 1, 2025
69.21 ILS
The Pulsenmore EBITDA Growth YoY history
YEAREBITDA Growth YoYYoY
69.21 %+169.53%
25.68 %-227.09%
-20.21 %-73.65%
-76.69 %-18.01%
-93.54 %-58.80%
-227.06 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pulsenmore Stock analysis

What does Pulsenmore do? Pulsenmore Ltd. generates revenue through the sale of its two miniaturized ultrasound systems, PulseNmore ES and PulseNmore FC, designed for home use in remote clinical diagnosis. The PulseNmore ES targets pregnant women requiring regular ultrasound monitoring, while PulseNmore FC caters to women undergoing in vitro fertilization needing follicle size assessments. Both systems integrate with smartphones, enabling patients to conduct tests at home and share results online with healthcare providers. The company also monetizes through software delivery for its devices, enhancing user experience and data management. The primary buyers of PulseNmore ES are pregnant women seeking convenient, clinic-free monitoring, and healthcare providers managing prenatal care remotely. PulseNmore FC is purchased by women undergoing in vitro fertilization, often through fertility clinics or medical centers that recommend the device. These segments value the convenience of home-based diagnostics and seamless telehealth integration without requiring in-person visits. Pulsenmore Ltd. focuses on global markets for its portable ultrasound solutions, serving patients in remote or underserved areas who benefit from telehealth-enabled diagnostics. The company’s products are positioned as cost-effective alternatives to traditional clinic visits, appealing to both end-users and healthcare institutions aiming to reduce operational costs while maintaining patient care quality. Pulsenmore is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pulsenmore stock

Year-over-Year EBITDA Growth of Pulsenmore is 69.21 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBITDA Growth Pulsenmore since 2006 – with annual values, charts, and detailed analysis.

EBITDA growth measures the percentage change in EBITDA compared to the prior year. It shows changes in operating cash earnings before capital structure effects.

To evaluate Year-over-Year EBITDA Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBITDA Growth.

Year-over-Year EBITDA Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBITDA Growth's Pulsenmore historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Pulsenmore

All Key Metrics — Pulsenmore